[go: up one dir, main page]

NO20065835L - Medicines containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions - Google Patents

Medicines containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Info

Publication number
NO20065835L
NO20065835L NO20065835A NO20065835A NO20065835L NO 20065835 L NO20065835 L NO 20065835L NO 20065835 A NO20065835 A NO 20065835A NO 20065835 A NO20065835 A NO 20065835A NO 20065835 L NO20065835 L NO 20065835L
Authority
NO
Norway
Prior art keywords
arylpiperazines
sulfamoyl
prophylaxis
obesity
treatment
Prior art date
Application number
NO20065835A
Other languages
Norwegian (no)
Inventor
Peter-Colin Gregory
Harald Waldeck
Jochen Antel
Michael Wurl
Dania Reiche
Uwe Reinecker
Uwe Schoen
Michael Firnges
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20065835L publication Critical patent/NO20065835L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelsen av kjente og nye N-sulfamoyl-N'arylpiperaziner og deres fysiologisk kompatible syreaddisjonssalter til profylakse eller behandling av overvekt og beslektede tilstander.The present invention relates to the use of known and novel N-sulfamoyl-N'arylpiperazines and their physiologically compatible acid addition salts for the prophylaxis or treatment of obesity and related conditions.

NO20065835A 2004-05-19 2006-12-18 Medicines containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions NO20065835L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57223604P 2004-05-19 2004-05-19
EP04102210 2004-05-19
PCT/EP2005/052281 WO2005110413A2 (en) 2004-05-19 2005-05-18 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Publications (1)

Publication Number Publication Date
NO20065835L true NO20065835L (en) 2007-02-16

Family

ID=34969508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065835A NO20065835L (en) 2004-05-19 2006-12-18 Medicines containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions

Country Status (11)

Country Link
EP (1) EP1750712A2 (en)
JP (1) JP2007538054A (en)
CN (1) CN1997370B (en)
AU (1) AU2005244450B2 (en)
BR (1) BRPI0510137A (en)
CA (1) CA2567166A1 (en)
IL (1) IL178903A0 (en)
MX (1) MXPA06013299A (en)
NO (1) NO20065835L (en)
RU (1) RU2395503C2 (en)
WO (1) WO2005110413A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
KR101047274B1 (en) * 2006-01-23 2011-07-06 에프. 호프만-라 로슈 아게 Cyclohexyl Sulfonamide Derivatives Having H3 Receptor Activity
US8455432B2 (en) 2007-01-25 2013-06-04 Verva Pharmaceuticals Ltd. Insulin sensitisers and methods of treatment
ES2543754T3 (en) * 2009-04-22 2015-08-21 Axikin Pharmaceuticals, Inc. CCR3 antagonists of arylsulfonamide
RU2445963C2 (en) * 2010-07-09 2012-03-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical antidiabetic composition
HUE045701T2 (en) 2013-03-13 2020-01-28 Forma Therapeutics Inc 2-Hydroxy-1- {4 - [(4-phenylphenyl) carbonyl] piperazin-1-yl} ethan-1-one derivatives and related compounds as fatty acid synthase (FASN) inhibitors for the treatment of cancer
GB201410817D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D Therapeutic agents
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748125A (en) * 1954-04-26 1956-05-29 American Cyanamid Co 1-substituted-4-sulfamylpiperazine and method of preparing the same
DE1964441A1 (en) 1969-01-02 1970-07-16 Sandoz Ag Agent for combating unwanted plant growth
US3709677A (en) * 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
SU1646258A3 (en) * 1989-02-08 1996-02-10 Институт биохимии Литовской АН 5-aminonaphthalene-1-sulfamides as substrate detectable groups for peptidase analysis by fluorescence
DE4025387A1 (en) 1990-08-10 1992-02-13 Hoechst Ag SUBSTITUTED PYRIMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS REAGENTS
NZ254550A (en) * 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
JPH09504508A (en) * 1993-09-28 1997-05-06 チバ−ガイギー アクチエンゲゼルシャフト Acrylated sulfonamides as insecticides and acaricides
PL334846A1 (en) * 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
DE10035227A1 (en) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Selection and use of lipogenesis inhibitors for the treatment and prevention of obesity
AU2003218736B2 (en) * 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
DE60325051D1 (en) * 2002-06-06 2009-01-15 Boehringer Ingelheim Pharma SUBSTITUTED 3-AMINO-THIENO (2,3-b) PYRIDINE-2-AMIDE AND MANUFACTURING METHOD AND THEIR USE
WO2005005382A2 (en) * 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
KR101280095B1 (en) 2004-08-28 2013-09-09 아스트라제네카 아베 Pyrimidine sulphonamide derivatives as chemokine receptor modulators

Also Published As

Publication number Publication date
CN1997370B (en) 2011-06-01
CN1997370A (en) 2007-07-11
EP1750712A2 (en) 2007-02-14
AU2005244450B2 (en) 2010-08-19
IL178903A0 (en) 2007-03-08
RU2395503C2 (en) 2010-07-27
RU2006144812A (en) 2008-06-27
AU2005244450A1 (en) 2005-11-24
JP2007538054A (en) 2007-12-27
WO2005110413A3 (en) 2006-07-13
CA2567166A1 (en) 2005-11-24
WO2005110413A2 (en) 2005-11-24
BRPI0510137A (en) 2007-10-02
MXPA06013299A (en) 2007-02-02

Similar Documents

Publication Publication Date Title
NO20064599L (en) Substituted morpholine and thiomorpholine derivatives
NO20063599L (en) Further heterocyclic compounds and their use as metabotrophic glutamate receptor antagonists
NO20063468L (en) Triazole compounds and their use as metabotrophic glutamate receptor antagonists
NO20070081L (en) Sulfamate and sulfamide derivatives for the treatment of epilepsy and related diseases
NO20082673L (en) New 2-amino-imidazol-4-one compounds and their use in the preparation of a drug to be used for the treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia
NO20070224L (en) 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof
NO20072461L (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
NO20076638L (en) New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor
NO20071343L (en) Substituted phenylaminothiazoles and their use
NO20091655L (en) Substituted dihydropyrazolones for the treatment of cardiovascular and hematological diseases
NO20083905L (en) New pyron-indole derivatives and process for their preparation
NO20081844L (en) Therapeutic compounds
DE60229530D1 (en) SUBSTITUTED PIPERAZINE AS MODULATORS OF MELANOCORTINRECEPTOR
NO20063469L (en) Polyeheterocyclic compounds and their use as metabotrophic glutamate receptor antagonists
NO20054848L (en) Substituted p-diaminobenzene derivatives
NO20064347L (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
NO20080745L (en) New peptides for use in the treatment of obesity
NO20084418L (en) Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
NO20050851L (en) Caspase Inhibitors and Uses thereof
NO20075781L (en) Diarylsulfone sulfonamides and their use
ATE475650T1 (en) POSITIVE ALLOSTERIC QUINOLONE M1 RECEPTOR MODULATORS
SE0403006D0 (en) New compounds
NO20082269L (en) NEW PIPERAZINES AS ANTIMAL ARIA AGENTS
CY1108794T1 (en) CYCLOEXANE SPIRACYCLICAL DERIVATIVES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application